BIOGEN INC. — Director's Dealing 2021

Dec 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SANGAMO THERAPEUTICS, INC (SGMO)
CIK: 0001001233
Period of Report: 2021-12-23

Reporting Person: BIOGEN INC. (10% Owner)
Reporting Person: Biogen MA Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-23	Common Stock	S	81187	$8.5547	Disposed	24155830	Indirect
2021-12-27	Common Stock	S	600	$8.56	Disposed	24155230	Indirect

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.65, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.